TGTX: TG Therapeutics, Inc. Stock

by  •  • Comments Off on TGTX: TG Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 5,110.54
Enterprise Value ($M) 5,175.73
Book Value ($M) 222.36
Book Value / Share 1.53
Price / Book 22.98
NCAV ($M) 211.03
NCAV / Share 1.45
Price / NCAV 24.22

Profitability (mra)
Return on Invested Capital (ROIC) 0.05
Return on Assets (ROA) 0.07
Return on Equity (ROE) 0.14

Liquidity (mrq)
Quick Ratio 5.03
Current Ratio 6.25

Balance Sheet (mrq) ($M)
Current Assets 566.36
Assets 577.69
Liabilities 355.33
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 329.00
Operating Income 41.93
Net Income 23.38
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -40.52
Cash from Investing -1.04
Cash from Financing 128.53

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
01-08 13G/A Vanguard Group Inc 10.01 14.08
11-14 13G/A Darwin Global Management, Ltd. 0.00 -100.00
10-07 13G/A BlackRock, Inc. 14.20

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-03 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024. ☐ TRANSITION REPORT PURSUANT TO SECT
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-09 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. ☐ TRANSITION REP
2024-05-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-07 858,389 3,495,345 24.56
2025-03-06 1,006,860 3,713,694 27.11
2025-03-05 447,860 1,944,405 23.03
2025-03-04 751,250 4,112,256 18.27

(click for more detail)

Similar Companies
TCRT – Alaunos Therapeutics, Inc. TELO – Telomir Pharmaceuticals, Inc.
TENX – Tenax Therapeutics, Inc. THAR – Tharimmune, Inc.
THTX – Theratechnologies Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: TG Therapeutics